ClinicalTrials.gg
RecruitingNCT05424978AsgctsisUpdated Jan 26, 2024

Application of Standardized Green Channel Treatment System for Ischemic Stroke in Xi 'an

An observational study in Acute Ischemic Stroke, Thrombolysis and Endovascular Treatment, sponsored by Xi'an No.3 Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-01-26.

Sponsored by Xi'an No.3 Hospital · Observational

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 3 months ago, but the record still lists the study as recruiting.
  • Started Jun 2022; still recruiting 4 years 5 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
3,600
Ages
18 Years to 100 Years
Sex
All
01

Study summary

Objective: To observe the practical application of the standardized green channel treatment system for stroke in Xi 'an in the real world. Methods: Clinical data and information of patients with acute ischemic stroke who received standardized green channel treatment for stroke were collected, and a multicenter observational clinical study was carried out in the real world to evaluate the prognosis, mortality, incidence of asymptomatic and symptomatic cerebral hemorrhage, incidence of pneumonia, and recurrence rate of stroke after 90 days.

Read the detailed description

The standardized green channel treatment system for acute ischemic stroke includes: Triage nurse triage timely, rapid assessment emergency doctor, suspected stroke the green channel, immediately start in the green channel of stroke accompanied by doctors and nurses stroke patients improve CT examination, intravenous thrombolysis or CT room, emergency room if considering large vascular lesions and the onset time in 6 hours, and rapidly to international for endovascular treatment, if the onset time of more than 6 hours, Rapid evaluation of ischemic penumbra and vascular occlusion by multi-mode imaging. If there are indications for endovascular treatment, go to the cath room for endovascular treatment as soon as possible.

02

Conditions studied

  • Acute Ischemic Stroke
  • Thrombolysis
  • Endovascular Treatment

Browse trials for

03

In context

Ischemic Stroke

2,612 studies on the registry are indexed under Ischemic Stroke; 971 are open to participants now.

This study's planned enrollment of 3,600 is above the median of 300 across 771 observational studies indexed under Ischemic Stroke.

Browse Ischemic Stroke studies →

Lead sponsor

Xi'an No.3 Hospital is the lead sponsor of 7 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with acute ischemic stroke within 24 hours of onset; Receive standardized green channel treatment for stroke

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years old;
  • Consistent with the diagnosis of acute ischemic stroke;
  • 24 hours from onset to enrollment;

Exclusion criteria

Exclusion Criteria:

  • Patients who refuse to receive intravenous thrombolysis or intravascular intervention (including intravascular mechanical thrombolysis and arterial thrombolysis);
  • Stroke patients caused by brain tumor, brain trauma and blood diseases;
  • Those with a history of stroke and sequelae affecting the outcome assessment, namely, mRS 2 points before the onset of this stroke;
  • Combined with claudication osteoarthritis rheumatoid arthritis gout arthritis and other limb dysfunction and affect the neurological function examination;
  • Patients with severe hepatic and renal insufficiency (Note: Hepatic insufficiency refers to or AST values greater than 2 times the upper normal limit; Renal insufficiency refers to blood creatinine value greater than 2 times the normal upper limit);
  • Suffering from other serious life-threatening diseases with an expected survival time of less than 3 months;
  • Other diseases that limit neurological function evaluation or affect patient follow-up;
  • A woman planning to be pregnant or breastfeeding;
  • Currently participating in other clinical trials;
  • Refuse to participate in the registration of investigators
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
3,600 participants (estimated)
Target follow-up
90 Days
Patient registry
Yes

Interventions

  • OtherStandardized green channel treatment methods for stroke

    The measures include six measures: timely triage by triage desk nurses; Rapid evaluation by emergency room physician; If stroke is suspected, the green channel for nosocomial stroke should be activated immediately. Stroke greenway doctors and stroke nurses accompanied patients to complete CT examination; Intravenous thrombolysis in emergency rooms or CT rooms; Suspected macrovascular disease, if the onset time is less than 6 hours, quickly go to the catheter room for intravascular treatment; If the onset time was more than 6 hours, multi-mode imaging was used to quickly evaluate the ischemic penumbra and vascular occlusion, and then the patients were sent to the catheter room for intravascular treatment as soon as possible.

06

What researchers measure

Primary outcomes

  1. Rate of function independent

    Rate of modified Rankin Scale(mRS) score less than 3 at 90 days

    Time frame: 90 days after onset

Secondary outcomes

  1. Rate of mortality

    90-day mortality rate

    Time frame: 90 days after onset

  2. Rate of stroke recurrence

    90-day stroke recurrence rate

    Time frame: 90 days after onset

  3. Rate of cerebral hemorrhage and pneumonia

    Incidence of cerebral hemorrhage and pneumonia after thrombolysis or intravascular therapy

    Time frame: During hospitalization.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Data is managed by the project team and can be shared according to individual needs

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05424978
Lead sponsor
Xi'an No.3 Hospital
Responsible party
Sponsor
First posted
Jun 21, 2022
Start date
Jun 1, 2022
Primary completion
Jul 31, 2025 (estimated)
Completion
Jul 31, 2028 (estimated)
Last update
Jan 26, 2024

Study contacts

Mingze Chang, Doctor
Contact
changmingze191@163.com
8615609250698
Ye Tian, Doctor
study director · The dean

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion